Compare ARK Space & Defense Innovation ETF (ARKX) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Space & Defense Innovation ETF vs Twist Bioscience Corp — how do they compare? ARK Space & Defense Innovation ETF trades at $31.27, while Twist Bioscience Corp trades at $91.04 (market cap $5.64B). The key difference: Twist Bioscience Corp is trading nearer its 52-week high, ARK Space & Defense Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ARKX | TWST | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $37.74 | $102.88 |
52-Week Low | $24.97 | $24.16 |
Market Cap | — | $5.64B |
Enterprise Value | — | $5.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARK Space Exploration & Innovation ETF (ARKX) trades at $32.05, down 0.82% today amid bearish technical signals. The ETF shows neutral oscillator readings but bearish moving averages, with key support at $32 and resistance at $33. Recent news highlights ARKX as a popular alternative to direct SpaceX investment, with the space economy reaching $500 billion in backlog according to 24/7 Wall Street (2026-07-06).
ARKX offers diversified exposure to the growing space sector without single-stock IPO risk. The ETF's higher volatility and expense ratio compared to traditional aerospace ETFs present both growth potential and increased risk. SpaceX's 8.31% weighting provides significant upside exposure but also concentration risk in a high-valuation name.
Twist Bioscience (TWST) trades at $90.64, down 3.24% today, with a bullish technical signal from moving averages and ADX indicators. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a net income margin of -19.85%. Recent developments include AI-driven drug discovery collaborations and expansion of clonal genes offerings, positioning TWST in the growing synthetic biology market.
While analyst consensus is strongly bullish (77% buy ratings) with a $87.88 price target, investors face significant risks from persistent cash burn and competitive pressures. The stock's valuation appears stretched at 13.46x sales despite negative earnings, requiring careful monitoring of path to profitability and execution on AI partnerships for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Space & Defense Innovation ETF
ARKX is an actively managed ETF that invests in companies leading space exploration and defense innovation. It focuses on orbital and sub-orbital aerospace, reusable rockets, and enabling technologies like AI, robotics, and satellite systems.
Read more on ARKX →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
